Celgene's Otezla meets in Phase III for scalp psoriasis

Celgene Corp. (NASDAQ:CELG) said Otezla apremilast met the primary endpoint in the Phase III STYLE trial to treat moderate to severe plaque psoriasis of the scalp. A significantly greater proportion of patients who received twice-daily 30 mg Otezla achieved a Scalp Physician’s Global Assessment (ScPGA) score of clear or almost clear with at least a 2-point reduction from baseline at week 16 vs. placebo.

Otezla also met the secondary endpoint of a greater proportion of patients with at least a 4-point reduction from baseline in whole body itch numeric rating scale (NRS) score at week 16 vs. placebo. The double-blind, U.S. and Canadian trial enrolled 303 patients...